Boston Scientific Corp


  • No. 3 - Wall Street's Page Six Thursday, 12 Apr 2007 | 9:24 PM ET

    With global merger volume running 40% ahead of last year's record levels, and private equity barbarians scooping up one company after the next, the Wall Street rumor mill - in turn - is also running at a record pace.

  • Basketball player Vin Baker was a hot prospect with a great future. He was selected by the Milwaukee Bucks in the 1993 NBA draft, making the All-Star Team four straight times. However, in 1998 he exploded to an alarming 300 pounds, making his status as an active player impossible. Although he eventually lost some of the weight, he could no longer keep his dirty secret quiet -- he was an , and this fact would eventually end his career.

    A U.S. federal court has ruled that a stent made by Johnson and Johnson unit Cordis does not infringe a patent held by Boston Scientific, according to court documents.

  • What If Iran Goes Awry? Monday, 2 Apr 2007 | 6:42 PM ET

    Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.

  • Boston Scientific's stock slid on Monday while shares of Abbott Laboratories jumped after a study showed Abbott's drug-coated stent was better at treating clogged heart arteries.

  • Lightning Round for Friday, March 23 Friday, 23 Mar 2007 | 6:44 PM ET

    Sun Micro, Vodafone, Six Flags and more: Cramer tells you to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Getting a Better Look at Volcano Thursday, 15 Mar 2007 | 6:27 PM ET

    In the second part of Cramer’s new series on non-pharma healthcare stocks, he sheds some light on this medical-imaging company.

  • Boston Scientific May Sell Endosurgery Unit Stake Monday, 12 Mar 2007 | 5:57 PM ET

    Boston Scientific, saddled with debt and a depressed share price since buying Guidant last year, said on Monday it may sell a minority stake in its endosurgery business for more than $1 billion in a public offering.

  • Boston Scientific and Johnson & Johnson said on Monday that U.S. lawmakers have requested information from the companies on their drug-eluting stents to treat clogged heart arteries.

  • It's Time for the Lightning Round! Monday, 26 Feb 2007 | 6:45 PM ET

    Today, Cramer tells callers what he thinks of Boston Scientific, Moody's, McDonald's, Noble Energy and more.

  • Boston Scientific's earnings came in a penny below estimates on higher expenses related to its acquisition of Guidant.

  • Layoffs a Bitter Pill for Employees and Investors Tuesday, 23 Jan 2007 | 1:31 PM ET

    As I write this Pfizer shares are down about 2.5% in intra-day trading on top of the 1% loss yesterday.  Usually investors cheer when a company announces substantial cost cuts--10,000 jobs, as many as eight facility closures or sales, $1.5 billion-$2 billion in savings by the end of '08. Yesterday you could argue the move was simple selling on the news as the layoffs and cost cuts had been leaked a week ahead of the meeting.  But today ...

  • Dollars and Stents Friday, 22 Dec 2006 | 11:17 AM ET

    After the market close yesterday Pfizer, in an SEC filing, revealed that ousted Chairman and CEO Hank McKinnell will walk away with nearly $200 million in pension benefits, deferred compensation and other cash and stock including more than $300,000 in unused vacation time.  This is well above the pension benefits that had been reported earlier this year and includes money that had not previously been disclosed.  A Pfizer spokesman says the company is honoring its legal obligation to meet the terms of McKinnell's employment contract which was signed in 2001--"a different time in the company's history," he said.

  • Market Wrap: Stocks Slip Mostly On Weak Economic Report Thursday, 21 Dec 2006 | 4:53 PM ET

    Sellers outnumbered buyers on Wall Street after multiple reports signaled a slowdown in economic growth. CNBC's "Closing Bell" team sorted through the details.

  • CNBC's Schacknow: Breaking News Can Break A Producer Thursday, 21 Dec 2006 | 1:23 PM ET

    As The Stomach Turns:  Ah, the pressure of producing breaking news. I’ve done it enough times, yet I always find the monthly Philadelphia Fed report nerve wracking...

  • Boston Scientific has landed an exclusive contract to provide drug-coated stents to the Cleveland Clinic, one of the nation's most prominent cardiology centers, CNBC pharmaceuticals reporter Mike Huckman has learned.

  • CNBC's Huckman: Stent Battle Escalates Thursday, 21 Dec 2006 | 10:08 AM ET

    Within the last few hours CNBC's Pharmaceuticals Reporter Mike Huckman broke the news that Boston Scientific has locked up a huge account, but at what price?

  • Analyst: Christmas Isn't Over For Markets Monday, 11 Dec 2006 | 9:55 AM ET

    For traders, Christmas came early this year. A strong U.S. jobs report Friday and a rebound in the U.S. dollar have kicked up a bit of a "Santa Claus rally" in the markets. And at least one analyst says there are more gifts under the tree. Phil Dow, director of equity strategy at RBC Dain Rauscher, wouldn’t be surprised if we saw an additional percent or two before the year is through.

  • Update On FDA Panel: No Change On Stent Labels Friday, 8 Dec 2006 | 4:09 PM ET

    As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.

  • Greetings from the Gaithersburg, Maryland Hilton! That's where the FDA is holding the advisory committee meeting on the safety of drug-coated stents. For less high-profile FDA meetings this hotel and the Holiday Inn across the street (the FDA alternates between them) are just fine. But for a big meeting like this one the venue is way too small.